Ipamorelin and CJC-1295: GH secretagogues
How GH secretagogues work, how Ipamorelin, CJC-1295 without DAC and GHRP-6 differ, and what studies show about growth hormone.
Key findings
- GH secretagogues act on the pituitary axis and stimulate the body's own release of growth hormone.
- CJC-1295 is a GHRH analogue, while Ipamorelin and GHRP-6 act through the ghrelin receptor.
- The CJC-1295 version without DAC has a shorter half-life than the version with DAC.
- These are research compounds, not approved medicines; they may be prohibited in sport.
Growth hormone is one of the most tightly regulated molecules in the body. Its release is not constant but pulsatile — with pronounced peaks, mainly at night and after physical activity. GH secretagogues are compounds that seek to stimulate these physiological pulses rather than replace them.
In this article we look at three common representatives: Ipamorelin, CJC-1295 without DAC and GHRP-6.
How does the pituitary axis work?
Growth hormone release is regulated mainly by two hypothalamic signals:
- GHRH (growth hormone-releasing hormone) stimulates synthesis and release;
- somatostatin inhibits release.
In the pituitary, GHRH acts through its own receptor, while ghrelin acts through the GHS-R1a receptor. Both signals interweave with feedback loops, including IGF-1, which is produced in the liver and inhibits further hormone release.
That is why any compound that intervenes in this axis has an indirect and context-dependent effect. This is the key difference from direct administration of recombinant hGH.
Three representatives
| Compound | Receptor | Distinguishing feature |
|---|---|---|
| Ipamorelin | GHS-R1a | Described as a more selective GH secretagogue |
| CJC-1295 without DAC | GHRH receptor | GHRH(1–29) analogue with a shorter duration of action |
| GHRP-6 | GHS-R1a | An earlier secretagogue, also associated with appetite |
Ipamorelin
Ipamorelin is a pentapeptide developed with the aim of greater selectivity. In studies it was observed to stimulate growth hormone release without an equally pronounced effect on cortisol or prolactin. This made it interesting for research into endocrine regulation.
Selectivity, however, is not absolute. Dose, model and concurrent factors influence which hormones will change.
CJC-1295 without DAC
CJC-1295 is a modified GHRH(1–29) analogue. The version with DAC binds to albumin and remains in circulation longer; the version without DAC lacks this group and has a shorter half-life.
A shorter half-life means more pulsatile exposure. This can be an advantage if you want to mimic the physiological rhythm, and a disadvantage if you want a constant level. The decision depends on the research question.
GHRP-6
GHRP-6 is one of the earlier GH secretagogues. In studies, alongside hormone release, increased appetite was also observed, and at higher doses an effect on prolactin and cortisol.
For body composition research this matters, because a change in appetite can itself change the outcomes. Without control of food intake, interpretation is difficult.
What does “pulsatile release” mean?
Growth hormone is not released at a constant concentration. Pulses matter because receptors and tissues respond to the pattern, not only to the average. Two strategies with the same total amount of hormone can therefore produce different biological responses.
Measurement is demanding: a single blood sample does not capture a pulse. Studies therefore often use frequent sampling or measure IGF-1 as an indirect indicator. Each approach has limitations.
What do the studies show?
Pharmacokinetic and pharmacodynamic studies have described how quickly compounds reach a peak and how long they remain active. Some smaller studies have examined effects on body composition, bone density or metabolic markers.
Crucially, however: there are no large, long-term randomised studies confirming the clinical benefit of these compounds in healthy adults. Nor is there sufficient data on the safety of long-term use.
Safety
Potential adverse effects associated with increased growth hormone release include:
- fluid retention and swelling;
- headache;
- fatigue;
- joint pain;
- changes in glucose levels.
In people with endocrine or metabolic conditions these risks may be greater. Any use outside a clinical trial is associated with uncertainty, so professional supervision is required.
Sport and regulation
GH secretagogues may be on the prohibited list in sport. Check WADA and national rules. They are not approved as medicines for general use in the EU.
Common thinking errors
- “A bigger dose = more hormone.” Feedback loops can limit the effect.
- “Natural stimulation is always safe.” Even endogenous hormone has systemic effects.
- “Ipamorelin is like hGH.” It is not; the mechanism is different and so is the profile.
- “Results in animals are transferable.” Endocrine systems differ between species.
Conclusion
GH secretagogues are a research tool for studying the pituitary axis, not a simple solution for body composition. Understanding receptors, half-lives and feedback loops is essential for any meaningful discussion.
View Ipamorelin, CJC-1295 without DAC and GHRP-6 in the catalogue.
Frequently asked questions about this topic
Do GH secretagogues contain growth hormone?
Which is stronger, Ipamorelin or CJC-1295?
Are GH secretagogues prohibited in sport?
How to cite
RuskiPeptidi Editorial Team. (2026). Ipamorelin and CJC-1295: GH secretagogues. RuskiPeptidi.com. https://ruskipeptidi.com/blog/ipamorelin-cjc-1295-gh-secretagogues/
Editorial policy
The content is reviewed and sourced. If you find an error, let us know — we will publish a correction.
How we prepare contentSources
RuskiPeptidi Editorial Team
Content is prepared by the RuskiPeptidi.com editorial team based on primary scientific sources, regulatory documents and manufacturer data. Every article is reviewed before publication, and sources are listed at the end of the text.
Editorial policy and sources